AR034857A1 - Compuestos heteroarilos que contienen nitrogeno, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de composiciones farmaceuticas - Google Patents

Compuestos heteroarilos que contienen nitrogeno, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de composiciones farmaceuticas

Info

Publication number
AR034857A1
AR034857A1 ARP010105703A ARP010105703A AR034857A1 AR 034857 A1 AR034857 A1 AR 034857A1 AR P010105703 A ARP010105703 A AR P010105703A AR P010105703 A ARP010105703 A AR P010105703A AR 034857 A1 AR034857 A1 AR 034857A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
hydrogen
alkyl
cycloalkyl
nitrogen
Prior art date
Application number
ARP010105703A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR034857A1 publication Critical patent/AR034857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto heteroarilo que contiene nitrógeno, que tiene la estructura de la fórmula (1) en la cual m, n y p son independientemente 0 o 1; A es -C(Z1)-, -C(Z1)-NH-, SO2 o un enlace covalente; donde Z1 es oxígeno o azufre; R1 es hidrógeno, alquilo optativamente sustituido, alquenilo optativamente sustituido, alquinilo optativamente sustituido, cicloalquilo optativamente sustituido, heterociclilo optativamente sustituido, arilo optativamente sustituido, o heteroarilo optativamente sustituido; R2 es hidrógeno, alquilo o cicloalquilo; o R1, R2 y A cuando se toman en conjunto con el átomo de nitrógeno al cual están unidos forman un heterociclo portador de nitrógeno; R3 es alquilo optativamente sustituido, cicloalquilo optativamente sustituido, heterociclilo optativamente sustituido, arilo optativamente sustituido, o heteroarilo optativamente sustituido, R4 es hidrógeno, alquilo optativamente sustituido, cicloalquilo optativamente sustituido, heterociclilo optativamente sustituido, arilo optativamente sustituido, o heteroarilo optativamente sustituido; T es -O-, -S(O)q, o -NR5-; en donde q es 0, 1 o 2 y R5 es hidrógeno, alquilo optativamente sustituido, cicloalquilo optativamente sustituido, heterociclilo optativamente sustituido, arilo optativamente sustituido, o heteroarilo optativamente sustituido, X1, X2 y X3 son independientemente -CR6 o nitrógeno, en donde R6 es hidrógeno, alquilo optativamente sustituido, cicloalquilo optativamente sustituido, heterociclilo optativamente sustituido, arilo optativamente sustituido, o heteroarilo optativamente sustituido; con la condición de que al menos uno de X1, X2 y X3 es nitrógeno. Y1 es alquileno inferior o carbonilo; Y2 es alquileno inferior u oxígeno; y Z es azufre, oxígeno o -NR5- con la condición de que cuando A es un enlace covalente, R1 y R2 ambos son hidrógeno, y Z es -NH-, m, n y p todos no pueden ser 0; y cuando m es 0 Y2 es metileno, y Z es -NH-, R3 no puede ser alquilo inferior; y cuando Z es -NH-, R4 no puede ser feniletilo; y cuando A es un enlace covalente, R1 y R2 ambos son hidrógeno, Y2 es metileno, y R4 es metilo o etilo, R3 no puede ser alquilo inferior o fenilo insustituido; y cuando A es un enlace covalente, R1 y R2 ambos son hidrógeno, T es oxígeno, Z es nitrógeno o Y2 es metileno, R4 no puede ser cicloalquilo o fenilo insustituido; que eleva la expresión celular del gen ABCA-1, promoviendo el flujo de colesterol de células y aumentando los niveles de HDL en el plasma de un mamífero, en particular seres humanos. Los compuestos son útiles para tratar una enfermedad e la arteria coronaria. También se describen composiciones farmacéuticas que comprenden dichos compuestos; un compuesto que baja el colesterol LDL y el uso de dichos compuestos para la preparación de las composiciones farmacéuticas.
ARP010105703A 2000-12-07 2001-12-07 Compuestos heteroarilos que contienen nitrogeno, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de composiciones farmaceuticas AR034857A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25191600P 2000-12-07 2000-12-07
US31327401P 2001-08-17 2001-08-17

Publications (1)

Publication Number Publication Date
AR034857A1 true AR034857A1 (es) 2004-03-24

Family

ID=26941895

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010105703A AR034857A1 (es) 2000-12-07 2001-12-07 Compuestos heteroarilos que contienen nitrogeno, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de composiciones farmaceuticas
ARP010105708A AR034858A1 (es) 2000-12-07 2001-12-07 Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP010105708A AR034858A1 (es) 2000-12-07 2001-12-07 Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento

Country Status (16)

Country Link
US (3) US6919339B2 (es)
EP (3) EP1341773A2 (es)
JP (4) JP2004521878A (es)
KR (3) KR20030059835A (es)
CN (2) CN1486302A (es)
AR (2) AR034857A1 (es)
AU (5) AU2002239508B9 (es)
CA (3) CA2430951A1 (es)
HU (2) HUP0400708A3 (es)
IL (3) IL156315A0 (es)
MX (2) MXPA03005120A (es)
NO (2) NO20032585L (es)
NZ (2) NZ526336A (es)
PL (1) PL361893A1 (es)
RU (1) RU2003120061A (es)
WO (3) WO2002046172A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365196B2 (en) * 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US6995285B2 (en) * 2000-12-07 2006-02-07 Cv Therapeutics, Inc. ABCA-1 elevating compounds
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
EP1463726A2 (en) * 2001-12-21 2004-10-06 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
AU2003226252A1 (en) * 2002-04-04 2003-10-20 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
AU2003228737A1 (en) * 2002-04-30 2003-11-17 The Trustees Of Columbia University In The City Of New York Compositions and methods relating to abca1-mediated cholesterol efflux
US6900244B2 (en) 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
BR0311282A (pt) 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
BR0314390A (pt) * 2002-09-17 2005-07-19 Pharmacia Corp Moduladores aromáticos dos receptores hepáticos x
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1699527A1 (en) 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
WO2005123718A2 (en) * 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
MX2007005129A (es) 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Compuesto de benceno que tiene 2 o mas sustituyentes.
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
JP2008521903A (ja) 2004-12-01 2008-06-26 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー
WO2006078986A2 (en) * 2005-01-21 2006-07-27 Vertex Pharmaceuticals Incorporated Quorum sensing modulators
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP2292209A3 (en) 2005-09-12 2011-05-04 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyramidine-sulfamide
US7579504B2 (en) * 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
US20080119571A1 (en) * 2006-06-07 2008-05-22 Reddy Us Therapeutics, Inc. Compositions and methods to enhance reverse cholesterol transport
EP2070908A4 (en) * 2006-09-07 2011-08-10 Univ Okayama Nat Univ Corp COMPOUND HAVING A BENZAMIDE SKELETER AND A SELECTIVE CYCLOOXYGENASE INHIBITORY ACTIVITY (COX-1)
JP5539734B2 (ja) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チオピリミジンベースの化合物およびその使用
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
EP2259790A1 (en) * 2008-02-07 2010-12-15 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8633233B2 (en) 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
WO2010123838A2 (en) * 2009-04-20 2010-10-28 Abbott Laboratories Novel amide and amidine derivatives and uses thereof
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
JP6337255B2 (ja) * 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CA2899646C (en) 2013-03-15 2021-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
AU2017388466B2 (en) 2016-12-29 2022-04-28 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
ES2906078T3 (es) 2017-01-23 2022-04-13 Cadent Therapeutics Inc Moduladores del canal de potasio
CN106977467A (zh) * 2017-03-22 2017-07-25 北京宜生堂医药科技研究有限公司 一种化合物及其制备方法与用途
CN106966997A (zh) * 2017-03-22 2017-07-21 北京宜生堂医药科技研究有限公司 一种化合物及其制备方法与用途
MD3664802T2 (ro) 2017-08-07 2022-07-31 Alkermes Inc Inhibitori biciclici ai deacetilazei histonei
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
CN113999184A (zh) * 2020-02-28 2022-02-01 深圳深信生物科技有限公司 一种胺基脂质化合物、其制备方法和应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937172A (en) * 1960-05-17 Alkoxxethylguanameses
DE1197613B (de) * 1960-05-07 1965-07-29 Bayer Ag Alterungs-, Ozon- und Ermuedungsschutzmittel
DE1220860B (de) * 1964-09-26 1966-07-14 Bayer Ag Verfahren zur Herstellung trisubstituierter s-Triazine
US3413285A (en) * 1965-07-09 1968-11-26 Ciba Geigy Corp Amino-acetylamino-cholestanes
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2263110B2 (de) * 1972-12-22 1980-01-31 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren 2-Amino-4-phenyläthylamino-6-phenoxymethyl-1 ^-triazine und Verfahren zu ihrer Herstellung
ES467739A1 (es) * 1977-03-16 1979-07-01 Hoechst Ag Procedimiento para la preparacion de compuestos de bisbenci-midazolil sustituidos
US4357633A (en) 1979-07-11 1982-11-02 Buechler Lester W Engraving apparatus and method
US4892946A (en) * 1979-11-30 1990-01-09 E. I. Du Pont De Nemours And Company Agricultural sulfonamides
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
IT1211096B (it) * 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4387105A (en) * 1982-01-26 1983-06-07 American Cyanamid Company Methods of treating atherosclerosis with dialkylureas and dialkylthioureas
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE3643683A1 (de) * 1986-12-20 1988-07-07 Bayer Ag Farbstoffe
US4959092A (en) * 1987-06-03 1990-09-25 Mitsubishi Kasei Corporation Substituted phenyl (or pyridyl) urea compound and herbicidal composition containing the same as active ingredient
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
AU606808B2 (en) * 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
JPH0745508B2 (ja) * 1988-06-29 1995-05-17 株式会社大塚製薬工場 カルボン酸アミド誘導体
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
CA2118907A1 (en) 1991-09-13 1993-04-01 Akira Yoshida Tricyclic heterocyclic compound
JPH05194475A (ja) * 1991-09-13 1993-08-03 Sankyo Co Ltd 三環性ヘテロシクリル化合物
HUT73813A (en) 1993-06-30 1996-09-30 Wellcome Found Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
US5362744A (en) * 1993-11-22 1994-11-08 Warner-Lambert Company Tetrazole-substituted urea acat inhibitors
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
DE19536891A1 (de) * 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
WO1997014681A1 (en) * 1995-10-16 1997-04-24 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as h+-atpases
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
JPH10259311A (ja) * 1997-03-19 1998-09-29 Sumitomo Chem Co Ltd アゾ化合物及びそれを含有する染料系偏光膜
WO1999000121A1 (en) * 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
AR015514A1 (es) 1998-02-10 2001-05-02 Novartis Ag Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
CA2381008A1 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001047921A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis

Also Published As

Publication number Publication date
US20020128266A1 (en) 2002-09-12
US6548548B2 (en) 2003-04-15
US6919339B2 (en) 2005-07-19
CA2436662A1 (en) 2002-06-13
AU2597802A (en) 2002-06-18
EP1377283A2 (en) 2004-01-07
JP2004515498A (ja) 2004-05-27
AU2002239508B9 (en) 2005-09-08
WO2002046172A3 (en) 2003-02-06
WO2002046181A2 (en) 2002-06-13
NO20032585D0 (no) 2003-06-06
IL156167A (en) 2010-02-17
KR20040025879A (ko) 2004-03-26
CN1478085A (zh) 2004-02-25
US20020082257A1 (en) 2002-06-27
PL361893A1 (en) 2004-10-04
WO2002046141A3 (en) 2003-02-06
CA2431005A1 (en) 2002-06-13
RU2003120061A (ru) 2004-11-27
MXPA03005050A (es) 2004-04-02
US20020111364A1 (en) 2002-08-15
AU2002225978B2 (en) 2005-08-11
WO2002046181A3 (en) 2002-12-27
AU2002239508B8 (en) 2005-09-01
AU2002239535A1 (en) 2002-06-18
JP2004523496A (ja) 2004-08-05
NZ526336A (en) 2004-11-26
NO20032587L (no) 2003-07-31
WO2002046141A2 (en) 2002-06-13
HUP0400708A2 (hu) 2004-07-28
CN1486302A (zh) 2004-03-31
AU3950802A (en) 2002-06-18
NO20032585L (no) 2003-07-21
HUP0400689A3 (en) 2007-05-29
JP2004521878A (ja) 2004-07-22
CA2430951A1 (en) 2002-06-13
IL156315A0 (en) 2004-01-04
EP1341773A2 (en) 2003-09-10
IL156167A0 (en) 2003-12-23
JP2009149602A (ja) 2009-07-09
HUP0400708A3 (en) 2007-10-29
AR034858A1 (es) 2004-03-24
AU2002239508B2 (en) 2005-04-07
US6713650B2 (en) 2004-03-30
WO2002046172A2 (en) 2002-06-13
NO20032587D0 (no) 2003-06-06
JP4227807B2 (ja) 2009-02-18
EP1379517A2 (en) 2004-01-14
KR20030059835A (ko) 2003-07-10
KR100555192B1 (ko) 2006-03-03
NZ526037A (en) 2004-11-26
HUP0400689A2 (hu) 2004-06-28
KR20030060111A (ko) 2003-07-12
MXPA03005120A (es) 2004-03-10

Similar Documents

Publication Publication Date Title
AR034857A1 (es) Compuestos heteroarilos que contienen nitrogeno, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de composiciones farmaceuticas
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR041027A1 (es) Derivados de 1,2,3-triazol con actividad antimicrobiana particularmente fungicida
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
PE20050431A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
GEP20105124B (en) Novel macrocyclic inhibitors of hepatitis c virus replication
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
DE3889345D1 (de) Schimmelbekämpfungsmittel.
DE60217114D1 (de) Verbrückte bizyklische serinproteaseinhibitoren
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
ECSP045369A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
AR017982A1 (es) Preparacion combinada de estrogeno y antiestrogeno y su empleo
AR035884A1 (es) Derivado de amida aromatico sustituido, derivado de amina aromatico sustituido con un grupo fluoroalquilo util como intermediario para obtener el mismo, insecticida para agrohorticultura que lo contiene y metodo para usar este ultimo
ES2248498T3 (es) Derivados amidas, sulfonamidas o carbamatos aromaticos de acrilonitrilo y composiciones cosmeticas fotoprotectoras que los contienen.
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
BR0111594A (pt) Pirimidinas, processo para a preparação de pirimidinas, compostos, composição fungicida, e, método papa combater fungo em um local
CO5660264A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DK1468692T3 (da) Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom
CO5050264A1 (es) Derivados de 6-azauracilo como inhibidores il-5 procedimientos para su preparacion y composiciones farmaceuticas que comprenden dichos derivados
EA199900648A1 (ru) Замещенные производные (1,3-бис(циклогексилметил)-1,2,3,6-тетрагидро-2,6-диоксо-9н-пурин-8-ил) фенила, их получение и их применение при лечении воспалительных состояний и иммунных расстройств
DE60201089D1 (de) 6-(2-chlor-6-fluor-phenyl)-triazolpyrimidine
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
PE20010300A1 (es) Preparacion de piperidin-4-onas sustituidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure